References noted with a yellow highlight refer to human patients.
Brown BN, Valentin JE, Stewart-Akers AM “Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component.” Biomaterials 2009;30:1482-1491.
Valentin JE, Stewart-Akers AM, Gilbert TW “Macrophage participation in the degradation and remodeling of ECM scaffolds.” Tissue Engineering Part A 2009 Jan 6. [Epub]
Kim MS, Ahn HH, Shin YN “An in vivo study of the host tissue response to subcutaneous implantation of PLGA- and/or porcine small intestinal submucosa-based scaffolds.” Biomaterials 2007;28:5137-5143.
Palmer EM, Baum LG, Van Seventer GA. “Small Intestinal Submucosa (SIS) induces loss of mitochondrial integrity and caspase-dependent apoptosis in human T cells.” Tissue Engineering 2003;9:307-314.
Metzger DW. “Immune responses to tissue-engineered extracellular matrix used as a bioscaffold.” Annals of the New York Academy of Sciences 2002;961:335-336.
Harlan DM, Karp CL, Matzinger P “Immunological concerns with bioengineering approaches.” Annals of the New York Academy of Sciences 2002;961:323-330.
Palmer EM, Beilfuss BA, Nagai T “Human helper T cell activation and differentiation is suppressed by porcine small intestinal submucosa.” Tissue Engineering 2002;8:893-900.
Allman AJ, McPherson TB, Merrill LC “The Th2-restricted immune response to xenogeneic small intestinal submucosa does not influence protective immunity to viral and bacterial pathogens.” Tissue Engineering 2002;8:53-62.
Raeder RH, Badylak SF, Sheehan C “Natural anti-galactose alpha1,3 galctose antibodies delay, but do not prevent the acceptance of extracellular matrix xenografts.” Transplant Immunology 2002;10:15-24.
Allman AJ, McPherson TB, Badylak SF “Xenogeneic extracellular matrix grafts elicit a th2-restricted immune response.” Transplantation 2001;71:1631-1340.
McPherson TB, Liang H, Record RD “Gal alpha (1,3) Gal epitope in porcine small intestinal submucsa (SIS).” Tissue Engineering 2000;6:233-239.
